ima970a
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 18, 2017 (NCT03203005)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06218511 | Phase 1 | Nov 22, 2022 | Fondazione Giovanni Pascale |
| NCT03203005 | Phase 1/Phase 2 (Phase 2) | Sep 18, 2017 | CureVac AG, European Commission, Fondazione Giovanni Pascale, immatics Biotechnologies GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fondazione Giovanni Pascale | Academic/Hospital | 2 | 2 | 2 | 2017 |
| CureVac AG | For profit | 1 | 0 | 1 | 2017 |
| European Commission | Government | 1 | 0 | 1 | 2017 |
| immatics Biotechnologies GmbH | For profit | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1